| Line Item | 2026-01-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.3M | +625.3% | +186.0% |
| SG&A Expense | $919K | +11.8% | +55.7% |
| Operating Income | -$2.2M | -120.2% | -111.8% |
| Interest Expense | $1K | -49.5% | -33.8% |
| Net Income | -$2.2M | -119.7% | -111.6% |
| EPS (Basic) | -$0.58 | -93.3% | -205.3% |
| EPS (Diluted) | -$0.58 | -93.3% | -205.3% |
| Line Item | 2026-01-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.7M | -39.0% | -19.2% |
| Current Assets | $3.7M | -21.6% | -6.3% |
| Total Assets | $4.0M | -20.6% | -3.2% |
| Total Liabilities | $1.9M | +158.9% | +155.9% |
| Stockholders' Equity | $2.2M | -50.1% | -36.7% |
| Line Item | 2026-01-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.3M | — | — |
| Investing Cash Flow | -$90K | — | — |
| Financing Cash Flow | $4.0M | — | — |